PTPI earnings analysis
What we found in PTPI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not include the financial statements or MD&A results needed to assess revenue, margins, EPS, segment performance, or free cash flow for the quarter. Liquidity is the central concern: the Company used $1,648,127 in operating cash during the first six months of 2026 and held $3,488,595 in cash at June 30, 2026, leading management to state substantial doubt about going-concern status. The filing also reports ineffective disclosure controls and 3 ongoing material control deficiencies, while providing no quantitative guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Liquidity Metrics Disclosed
- Cash used in operations was $1,648,127 during the six months ended June 30, 2026, while cash on hand was $3,488,595 at quarter-end.
- Control Remediation Ongoing
- Management has developed a remediation plan for 3 internal-control deficiencies involving oversight, segregation of duties, and IT access controls, and continues to use an external consultant.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Going-Concern Doubt
- Management states there is substantial doubt about the Company’s ability to continue as a going concern because it does not have sufficient resources to fund operations for the next 12 months. Cash used in operations was $1,648,127 for the six months ended June 30, 2026, versus a cash balance of $3,488,595.
- Dependence on Additional Capital
- The Company states it will need to raise additional capital to finance losses and negative operating cash flows, with no assurance it can raise funds on favorable terms. Failure to commercialize products and raise capital could require the Company to reduce activities, curtail operations, or cease operations.
- Ineffective Disclosure Controls
- Disclosure controls and procedures were deemed ineffective as of June 30, 2026. Management identifies 3 material control deficiencies: insufficient monitoring and oversight, impracticable segregation of duties due to department size, and inadequate IT access controls.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the extracted 10-Q. Management states that additional capital will be needed to finance losses and negative operating cash flows, but does not provide a funding amount or timing.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Petros Pharmaceuticals reported a net loss of $987,036 for Q1 2026, down from a $2.26 million loss in Q1 2025, signaling reduced losses amid its strategic pivot to a self-care market focus. However, the company…
- 10-K · April 15, 2026
- Petros has pivoted from selling prescription ED products to developing a licensable Rx-to-OTC technology platform composed of a SaaS hosting layer and a potential SaMD consumer interface. The company is very early stage…
- 10-Q · November 13, 2025
- Petros’ 2025 Q3 results reflect a transition from its historical commercial businesses (assignment/ABC and Vivus termination) into an early-stage technology/self-care strategy. The company reported a Q3 GAAP loss of…
- 10-Q · August 14, 2025
- Petros’ 10-Q for the quarter ended June 30, 2025 shows a quarter-level GAAP profit of $5,432,846 driven by a $6,973,302 gain from the assignment of subsidiaries and the Vivus settlement, while continuing operations…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PTPI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever